MK-2060 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease (ESRD)
Conditions
End-Stage Renal Disease (ESRD), End-Stage Kidney Disease (ESKD), Kidney Failure, Chronic
Trial Timeline
Jun 14, 2023 → Feb 15, 2024
NCT ID
NCT05769595About MK-2060 + Placebo
MK-2060 + Placebo is a phase 1 stage product being developed by Merck for End-Stage Renal Disease (ESRD). The current trial status is completed. This product is registered under clinical trial identifier NCT05769595. Target conditions include End-Stage Renal Disease (ESRD), End-Stage Kidney Disease (ESKD), Kidney Failure, Chronic.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06582602 | Phase 1 | Completed |
| NCT05769595 | Phase 1 | Completed |
| NCT06843993 | Phase 1 | Completed |
| NCT05656040 | Phase 1 | Completed |
| NCT05027074 | Phase 2 | Completed |
| NCT03873038 | Phase 1 | Completed |
Competing Products
20 competing products in End-Stage Renal Disease (ESRD)